Lower-dose treatment might one day suit certain patients, but she said, "Researchers need strong clinical trials first." She outlined what would have to come together: studies testing lower doses directly rather than in theory, proof that the results hold up over years without significant weight re-gain, a clearer picture of who benefits most, consistent manufacturing standards, and regulatory review of the evidence
Small and large fiber neuropathy in those with type 1 and type 2 diabetes: a 5-year follow-up study
Does Dermatology Office Offer Options for Facial Volume Loss After Weight Loss
For example, Topiramate can increase the risk of kidney stones
Conclusions Increasing evidence demonstrated that MTHFR polymorphism including C677T and A1298C is associated with psychiatric diseases
As of September 2023, the FDA has banned 503A compound pharmacies from producing many peptides due to the lack of data showing their safety and efficacy